Northern Trust Corp Has $10.48 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Northern Trust Corp boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 7.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 792,750 shares of the company's stock after purchasing an additional 55,144 shares during the period. Northern Trust Corp owned about 0.93% of Syndax Pharmaceuticals worth $10,480,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in SNDX. R Squared Ltd bought a new position in shares of Syndax Pharmaceuticals in the 4th quarter valued at about $26,000. Virtus ETF Advisers LLC grew its holdings in shares of Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after acquiring an additional 827 shares in the last quarter. Cape Investment Advisory Inc. grew its holdings in shares of Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after acquiring an additional 3,927 shares in the last quarter. KBC Group NV grew its holdings in shares of Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock valued at $92,000 after acquiring an additional 3,559 shares in the last quarter. Finally, Optimize Financial Inc bought a new position in shares of Syndax Pharmaceuticals in the 4th quarter valued at about $152,000.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Citigroup cut their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Scotiabank raised their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research note on Tuesday, May 6th. Finally, Guggenheim reiterated a "buy" rating and issued a $32.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $35.91.

Syndax Pharmaceuticals Trading Up 13.7%

SNDX stock traded up $1.27 during mid-day trading on Tuesday, hitting $10.57. 3,551,520 shares of the company were exchanged, compared to its average volume of 1,739,784. The business has a 50 day simple moving average of $11.97 and a 200-day simple moving average of $13.94. The stock has a market capitalization of $909.52 million, a PE ratio of -2.91 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.06. The company had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. During the same quarter last year, the business earned ($0.85) earnings per share. The company's revenue was up 1900.0% on a year-over-year basis. Equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).